SUMMARY Fourteen experiments have been completed to develop an improved primate model of chronic cerebral vasospasm. Results show that by placing a 0.4 mm needle through the intracranial internal carotid artery and percutaneously removing it the following day, cerebral vasospasm is regularly present five days later. There has been no mortality. The results of two monkeys followed with serial angiograms suggest that spasm first appears four days following the subarachnoid hemorrhage and lasts at least eleven days. The results of all experiments show that the most affected vessel in each experiment is reduced to 62% of control diameters. Vasospasm involves cerebral arteries both ipsilateral and contralateral to the site of hemorrhage and extends to the most distal vessels which can be measured. Finally, a neurological defect has been regularly demonstrated on the side contralateral to the site of hemorrhage.
SINCE ITS RECOGNITION cerebral vasospasm (CVS)
has plagued the neurosurgeon, increased the risk of early surgery, forced surgical delay for days or weeks, exposed the patient to the risk of recurrent subarachnoid hemor rhage (SAH) and death. Consequently, considerable ef fort has been expended to study and treat CVS. Multiple therapies have been tried. Thus far, there is no consistent ly successful treatment for CVS.
One approach to the study of CVS has been via the use of animal models. To date, each model has been unable to accurately recreate the human experience of SAH and CVS. Most authors agree that an adequate model of CVS should include the use of a primate, the reliable produc tion of vasoconstriction without mortality, the use of a technique which injures the vessel wall and produces hemorrhage, the angiographic demonstration of CVS oc curring after a delay of a few days with constriction of vessels to approximately 50% of their control size and the prolongation of spasm for many days to a few weeks. Finally and importantly, the CVS should be accompanied by a neurological deficit which correlates with the terri tory of the demonstrated spasm.
The purpose of this presentation is to describe a pri mate model of CVS which fulfills to varying degrees all of these requirements. We have previously used this model to study the effects of intravenous (IV) nitroglycer in on CVS. 5 This work more fully describes the model and includes the results of experiments not previously reported.
Methods
Nine Macaca nemestrina monkeys weighing 4.3 to 15.5 kg were used in fourteen experiments. Those monkeys which were used for more than one experi ment were allowed a two month recovery period be tween experiments. Prior to use, monkeys were quar antined for 45 days and each was individually housed and fed ad libitum.
All monkeys were premedicated with ketamine (15 20 mg/kg IM) and atropine (0.1 mg); then a neurologi cal examination was completed by two observers. An IV was started and the monkeys were anesthesized with IV pentobarbital (5-8 mg/kg). They were then paralyzed with pancuronium (0.1 mg/kg IV) and endo trachially intubated. Respirations were controlled with a Harvard Respirator (Model 6). Heart rate, respira tions, and body temperature were continuously moni tored. Monkeys were warmed with a heating pad and temperatures maintained at 38°C ( ± 0.5°). Arterial blood gases were monitored to assure a normal pH, P 02 , and P C02 .
Baseline bilateral, transfemoral, anterior-posterior (AP), and lateral (LAT) carotid angiograms were per formed in all monkeys. After a recovery of at least one week, the neurological examination was repeated fol lowing premedication, and then a fronto-temporal craniectomy was created under pentobarbital anesthe sia, using hyperventilation and mannitol (1 gm/kg). A 0.15 to 0.4 mm round stainless steel needle was placed through both walls of the carotid artery at the origin of the posterior communicating artery after the arachnoid had been opened to expose the internal carotid artery. An attached suture was buried subcutaneously, and the dura, muscle, and scalp were closed.
The following day, the monkeys were anesthetized with ketamine and atropine as before, examined neuro logically, and the needle was removed percutaneously to create an SAH. They were then paralyzed and placed on a respirator as before. Carotid angiography was repeated and these angiograms were compared with controls.
Data Analysis
Measurements of arterial diameter in both the AP and LAT views were made at preselected sites using an optical micrometer (Finescale, Orange, California) which magnified the vessels six times and was accurate to 0.1 mm. Measurements were made by the same person (JGF) without knowledge of the condition at the time of angiography, using the technique described by du Boulay. 2 The AP and LAT values for each site from all experiments were combined and averaged to pro vide a single value for each experimental phase. Be cause an average value of all vessels tended to dilute PRIMATE MODEL OF CHRONIC CEREBRAL VASOSPASM/Frazee the maximum vascular change in any given animal, the vessel from each experiment which was most con stricted was identified and these measurements were combined to provide a single value for each phase of the experiment. These averages were expressed as a percent of the control.
Results
The results of fourteen experiments are shown in table 1. During the first six experiments a 0.15 mm needle was used to produce the SAH. Only half of the animals demonstrated CVS. In the subsequent eight experiments, larger needles were used, first a 0.3 mm andfinallya 0.4 mm needle. Vasospasm was produced in each of these experiments. None of the animals died during the study. In two experiments, serial angio grams were performed to follow CVS development and duration. Spasm was noted immediately after re moving the needle, but resolved by 24-28 hours. Chronic CVS was noted to begin about the fourth day and to persist through the eleventh day following nee dle removal.
Observation of individual vessel changes demon strated that the vessel most affected in each experiment was the anterior cerebral artery in eight of eleven in stances. The constriction of the most affected vessel ranged from 28% to 80% of control diameters, and averaged 62 percent (table 1) .
Observation of activity of the first six monkeys in their cages, failed to reveal a neurological abnormal ity. Formal neurological testing was then used in the last eight experiments and a neurological deficit was found in each case. The defect was a reflex hyperacti vity on the side contralateral to the CVS. Table 2 shows the results of the last eight experi ments which utilized the larger needles. The most con stricted vessel was narrowed to an average of 60% of its control size. When all vessels were averaged to gether, the degree of maximum constriction was 72% of controls. A comparison of the changes in vessel diameter for the side contralateral and ipsilateral to the SAH was made for three experiments (table 3) . The trend seen in table 2 was still present, with constriction seen throughout the arterial tree and with the distal anterior carotid artery being most affected. The results demon strate that SAH did affect vessels of both hemispheres of the brain.
Discussion
In 1968, Simeone et al. 9 described a primate model of vasospasm which involved the placement of a nee dle through the internal carotid artery and immediate withdrawal. These authors were able angiographically to demonstrate cerebrovasospasm at four days. There were, however, complications with the technique, and several monkeys died. Vasospasm did not always de- velop, and when it did, it did not last beyond seven days. Several authors have since used primates in mod els of spasm, [6] [7] [8] but each has had design weaknesses. Our model is an extension of these techniques and in the continued search for improvement in the prepara tion, we have found the following data. First, CVS was produced in every instance when we began to employ a large needle. This presumably produced a larger subarachnoid hemorrhage and was in keeping with the suggestion of Fisher et al. 3 that a larger subar achnoid hemorrhage increased the probability of de veloping cerebrovasospasm. Contrary to the exper ience of some others, none of our monkeys died from the effects of the SAH. Second, it is important to measure the vessel in each experiment which is most constricted, in contradistinction to averaging all vessel measurements. We reason that the most constricted vessel also has the lowest blood flow and is therefore more likely to be responsible for cerebral ischemia and a neurological deficit. In our experiments, the distal anterior cerebral artery (A 2 ) was the most affected. Because the A 2 segment is a single rather than a paired vessel in the monkey, a decrease in perfusion through this segment would affect the blood flow of both fron tal lobes. This fact may explain the difficulty in detect ing a neurological deficit in this or other animal models for a neurological deficit is usually demonstrated by comparing the right and left sides. When both sides are affected by CVS this method may not show abnormal ity, unless the methods of testing are sensitive to small er differences.
Third, table 3 shows that the distal as well as proxi mal vessels of the ipsilateral arterial tree are involved in vasospasm. This is in keeping with the suggestion of others that the more distal, angiographically invisible vessels might also be involved in spasm. If this is true, it could explain the occasional finding of a patient without detectible spasm who has a neurological defi cit following subarachnoid hemorrhage. Fourth, table 3 also demonstrates that cerebral vaso spasm affects the contralateral arterial tree. The contra lateral side then should not be considered normal and is not a good control for experiments dealing with subar achnoid hemorrhage and cerebrovasospasm. Finally, we have been able consistently to demon strate a neurological asymmetry which could be attrib uted to the CVS. The absence of any such neural defect has been a major drawback to previous models.
